Skip to content

Evaluate the efficacy of Gunpowder 3x in the Homoeopathic management of uncomplicated ABSSSI (Acute Bacterial Skin and Skin Structure Infection)

A Clinical trial to evaluate the efficacy of Gunpowder 3x in the Homoeopathic management of uncomplicated ABSSSI (Acute Bacterial Skin and Skin Structure Infection) - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/09/095357
Enrollment
50
Registered
2025-09-24
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L00-L08- Infections of the skin and subcutaneous tissue

Interventions

Intervention1: Gunpowder 3x as a Homoeopathic Medicine: The intervention will consist of Gunpowder 3x in triturated tablet form, administered orally in the dose of one or two tablet once or twice dail

Sponsors

Dr Aaratikumari Gohil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Clinically diagnosed with uncomplicated ABSSSI, such as minor abscess, furuncle, carbuncle, cellulitis, or impetigo. 2. Mild to moderate infection confirmed by SIRS Tool scoring. 3. Willingness to participate and provide written informed consent. 4. No prior antibiotic use in the last 7 days. 6. Patients of both sexes.

Exclusion criteria

Exclusion criteria: 1.Patients aged below 18 and above 60 years. 2.Complicated ABSSSI cases requiring hospitalization or surgical intervention. 3.Immunocompromised patients (e.g., HIV/AIDS, uncontrolled diabetes). 4.Pregnant or lactating women. 5.Any life-threatening condition, whether related to the current infection or due to underlying illness (e.g., active cancer, severe cardiac or respiratory disease, multi-organ failure). 6.Patients who will be unable to provide informed consent, including patients with cognitive impairment or psychiatric disorders that impair decision-making capacity.

Design outcomes

Primary

MeasureTime frame
Reduction in the severity of uncomplicated ABSSSI, measured by the change in total SIRS (Skin Infection Rating Scale) score from baseline to the end of treatment with Gunpowder 3x.Timepoint: At the baseline and at the end of each follow up

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr Aaratikumari Gohil

Anand Homoeopathic Medical and Research institute, Anand

drhetaltrivedi@gmail.com8200546255

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026